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In Vitro and In Vivo Evaluation of 64Cu-Radiolabeled
KCCYSL Peptides for Targeting Epidermal Growth
Factor Receptor-2 in Breast Carcinomas
Senthil R. Kumar,1,2 Fabio A. Gallazzi,3 Riccardo Ferdani,4 Carolyn J. Anderson,4
Thomas P. Quinn,1 and Susan L. Deutscher1,2
Abstract
Epidermal growth factor receptor-2 (EGFR-2) has been implicated in the pathogenesis of breast and other
carcinomas. In this report, we tested the ability of a bacteriophage selected peptide KCCYSL, radiolabeled with
64Cu, to image EGFR-2 expressing breast tumors in vivo by positron emission tomography (PET). We evaluated
and compared the in vivo tissue distribution and imaging properties of 64Cu-X-(Gly-Ser-Gly)-KCCYSL pep-
tide (X¼ 1,4,7,10, tetraazacyclododecane-N,N’,N’’,N’’’-tetracetic acid, [DOTA] 1,4,8,11-tetraazabicyclo[6.6.2]
hexadecane-4,11-diacetic acid [CB-TE2A], and 1,4,7-triazacyclononane-1,4,7-triacetic acid [NOTA] chelators) in a
human breast cancer xenograft mouse model using dual modality PET and computed tomography (CT). The
synthesized peptides DO3A-GSG-KCCYSL, CB-TE2A-GSG-KCCYSL, and NO2A-GSG-KCCYSL were purified,
radiolabeled with 64Cu, and evaluated for human breast cancer cell (MDA-MB-435) binding, 50% inhibitory
concentration, and serum stability. In vivo pharmacokinetic and small animal PET/CT imaging studies were
performed using SCID mice bearing MDA-MB-435 xenografts. The radiolabeled peptides bound with an 50%
inhibitory concentration of 42.0 10.2 nM (DO3A), 31 7.9 nM (CB-TE2A), and 44.2 6.6 nM (NO2A) to cul-
tured MDA-MB-435 cells. All of the radiolabeled peptides were stable in vitro. The tumor uptake of DO3A, CB-
TE2A, and NO2A peptides were 0.73 0.15 percent injected dose per gram (%ID/g), 0.64 0.08%ID/g, and
0.52 0.04%ID/g, respectively at 1 hour. Liver uptake for the 64Cu-DO3A-peptide (1.68 0.42%ID/g) was more
than that of the 64Cu-CB-TE2A-peptide (0.52 0.02% ID/g) and 64Cu-NO2A-peptide (0.48 0.05%ID/g) at 2
hours. PET/CT studies revealed successful tumor uptake of 64Cu-peptides at 2 hours postinjection. In vivo
kidney retention was observed with all of the radiolabeled peptides. The optimization of bifunctional chelators
improves the pharmacokinetic properties of the 64Cu-labeled GSG-KCCYSL peptide, which enables the selection
of a suitable peptide homolog as a PET imaging agent for EGFR-2 expressing breast carcinomas.
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Introduction
Epidermal growth factor receptor-2 (EGFR-2, erythro-blastic leukemia viral oncogene homolog 2 [ErbB-2]) is a
member of the EGFR family of transmembrane receptor ty-
rosine kinases.1,2 EGFR-2 expression has been reported to be
minimal in normal tissues,3 however, amplification of this
receptor occurs in approximately 30% of invasive breast
cancers and is associated with poor patient outcome.4–6
Hence, EGFR-2 has been identified as a target for cancer
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imaging and therapy. In the past few years, several groups
have developed antibodies, scFV fragments, and peptides7–10
that bind to EGFR-2.
Bacteriophage (phage) display libraries have been exten-
sively used to identify peptides that bind to a variety of tar-
gets including EGFR-2.11–13 Such phage-derived peptides,
once radiolabeled, hold promise as effective imaging agents
for identifying specific human tumors and evaluating re-
sponse to therapy. Although many imaging agents have
been developed using antibodies and proteins, they often
demonstrate low specificity, poor accumulation in target
tissue, sensitivity to reaction conditions, and slow clearance
properties in vivo.14,15 Accordingly, the number of radio-
pharmaceutials utilizing bifunctional chelator-conjugated
peptides for use in imaging has grown considerably over the
past few decades.16,17 Previously, we reported an 111In-
labeled phage display selected peptide, KCCYSL, for single
photon emission computed tomography (SPECT) imaging of
EGFR-2 expressing human breast tumor xenografts in
mice.18 However, due to the inherent limited sensitivity and
resolution of SPECT imaging, we were interested in evalu-
ating KCCYSL peptide for the positron emission tomogra-
phy (PET) targeted imaging of EGFR-2 expressing tumor(s).
PET imaging depends on the delivery of a targeting ligand
containing a positron emitting radionuclide to a tissue or
organ of interest. Copper-64 (t1/2¼ 12.7 hours) is an attractive
radionuclide for PET imaging that can be used for both di-
agnostic imaging and radionuclide therapy due to its dual
decay characteristics.19 The positron emissions (bþ:17.8%,
E bþmax¼ 653 keV; b
: 38.4%, E b-max¼ 578 keV) would allow
clinicians to image a patient using PET and provide thera-
peutic treatment using the same 64Cu-targeted pharmaceutical.
Unfortunately, the application of 64Cu-based radiopharma-
ceuticals has been hindered by the lack of stable copper
radiotracers in vivo. The high uptake and retention of copper-
containing compounds in the blood and liver are well
known.20,21 Therefore, more stable chelator-compounds are
necessary for in vivo studies using 64Cu.
Macrocyclic polyamine complexes of 1,4,8,11-tetraaza-
cyclotetradecane-N,N’,N’’,N’’’-tetracetic acid (TETA) and
1,4,7,10, tetraazacyclododecane-N,N’,N’’,N’’’-tetracetic acid
(DOTA) with copper have been shown to exhibit greater
kinetic inertness than acyclic analogs, but dissociation
of copper from both the chelators occurs in vivo.22–24
Weisman, Wong, and Anderson designed and characterized
the novel cross-bridged tetraaza-macrocyclic chelator 1,4,8,11-
tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-TE2A)
and demonstrated enhanced in vivo stability with significantly
less transchelation in the liver compared with 64Cu-TETA.
Thus, the rigidity of the cross-bridge system was credited
for the greater kinetic stability of the copper (II)-CB-TE2A
complex.25,26
Previous studies have also demonstrated the use of 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA), a 9-member
cyclic chelating agent for divalent copper.27–29 NOTA was
shown to have the capacity to form stable metal complex
with Cu2þ and other divalent and trivalent metals,29 which
overcome demetallation and tracer uptake in tissues such as
liver. Functionalized NOTA derivatives suitable for conju-
gation with proteins or peptides have been reported by dif-
ferent groups.29,30 In this study, we evaluated and compared
the in vitro and in vivo properties of DO3A-GSG-KCCYSL,
CB-TE2A-GSG-KCCYSL, and NO2A-GSG-KCCYSL radi-
olabeled with 64Cu. The radiolabeled peptides were tested
for cell binding, stability, pharmacokinetics, and tumor im-
aging in MDA-MB-435 human breast carcinoma xenografted
mice using small-animal PET/CT.
Materials and Methods
Reagents, cell lines, and animals
Reverse phase-high performance liquid chromatogra-
phy (RP-HPLC)–grade acetonitrile, and trifluoroacetic acid
were purchased from Fischer Scientific for HPLC analysis.
Copper-64 was purchased from Nuclear Reactor Laboratory,
University of Wisconsin. RPMI (Roswell Park Memorial In-
stitute) 1640 and human mammary epithelial cell media
were purchased from Invitrogen/Gibco. Bovine serum al-
bumin (BSA) and trypsin were obtained from Sigma Che-
mical Company. DOTA was purchased from Macrocyclics,
and CB-TE2A was synthesized as previously described.31
NOTA was procured from Chematech.
Normal mammary 184A1 cell line was obtained from
American Type Tissue Culture. The MDA-MB-435 cells were
maintained as monolayer cultures in RPMI-1640 medium
supplemented with 10% fetal bovine serum, sodium pyru-
vate, nonessential amino acids, and l-glutamine. 184A1 cells
were grown in (human mammary epithelial cell) media
supplemented with bovine pituitary extract. Cell cultures
were maintained at 378C in a 5% CO2 humidified incubator.
Sub-culturing was performed using standard trypsinization
procedures.
Four- to 5-week-old ICR-SCID (Institute of Cancer Re-
search severely compromised immunodeficient) female mice
were obtained from Taconic Farms. The mice were supplied
with sterilized water and irradiated rodent chow ad libitum.
Under gas anesthesia, each SCID mouse was subcutaneously
inoculated in the right shoulder with 1107 MDA-MB-435
cells. The tumors were allowed to grow for 3–4 weeks before
studies were performed. Animal studies were conducted in
accordance with the protocols approved by the institutional
animal care and use committee in accordance with U.S.
Public Health Service guidelines.
Solid-phase peptide synthesis
Peptides used in this study were synthesized using an Ad-
vanced Chem Tech 396 multiple peptide synthesizer (AAPP-
TEC) using standard Fmoc chemistry. Briefly, the resin
(50mmol) was deprotected using piperidine, resulting in the
formation of a primary amine from which the C-terminus of
the growing peptide was anchored. The Fmoc protected
amino acids (225mmol) with appropriate orthogonal pro-
tection were activated using O-benzotriazole-N,N,N0,
N0-tetramethyl-uronium-hexafluoro-phosphate, N-hydroxy-
benzotriazole, and N,N–diisopropylethylamine and sequen-
tially added to the resin. The metal chelators DOTA or NOTA
were coupled to the amino terminus of the linear GSG-KCCYSL.
In the case of CB-TE2A, the chelator was coupled to the peptide
on the resin through an intermediate preparation of the acti-
vated mixed anhydride by use of diisopropylcarbodiimide/
N,N-diisopropylethylamine/dimethylformamide as described
earlier.31 The resulting peptide was deprotected and cleaved
from the resin using a cocktail consisting of thioanisol, water,
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1,2-ethanedithiol, phenol, triisopropylsilane (2.5 ratio each), and
trifluoroacetic acid, respectively. The cleaved peptide was then
precipitated and washed using ether. The crude conjugate was
dried, weighed, and analyzed by Electrospray Ionization mass-
spectrometry (Thermo Finnigan). A NovaPak (HR-C18,
7.8300 mm, 6mM, 60 A˚) (Waters) column was used for the
purification of bulk amounts of peptides. The peptides were
peak purified to98% purity before in vitro cell binding assays.
Radiolabeling of peptides with 64Cu
Radiolabeling of DO3A-, CB-TE2A-, or NO2A-(GSG)-
KCCYSL with 64Cu was performed as follows: For DO3A-
(GSG)-KCCYSL, the peptide (50mg) was radiolabeled with
29.6 MBq 64Cu in 80 mL ammonium acetate (0.1 M) pH 5.5, at
858C for 90 minutes. Similarly, CB-TE2A-(GSG)-KCCYSL
(50 mg) was radiolabeled with 29.6 MBq 64Cu in ammonium
acetate (0.4 M) pH 7.0, at 858C for 90 minutes, and NO2A-
(GSG)-KCCYSL (50mg) was radiolabeled with 29.6 MBq 64Cu
in ammonium acetate (0.4 M) pH 6.8, at 758C for 60 minutes.
The reaction buffer was purged with nitrogen before radi-
olabeling to inhibit or minimize peptide oxidation. Also, as a
precautionary measure, the reaction buffers contained
0.05 mM Tris- (2-carboxyethyl) phosphine hydrochloride
(TCEP.HCl) to maintain cysteine reduction in the wake of
radiolytic oxidation during the peptide metal chelation pro-
cess. The resulting radiolabeled peptides were peak purified
using a Phenomenex Jupiter 5u C18 300 A˚ 2504.6 mm col-
umn and RP-HPLC (10%–95% acetonitrile/0.1% TFA) for 30
minutes to separate them from their nonradiolabeled coun-
terparts. The peak-purified peptides were concentrated using
Empore high efficiency (C18) extraction disk cartridges and
eluted with 400 mL of an 8:2 ethanol/sterile saline solution.
The ethanol was evaporated under a stream of nitrogen and
was diluted to the appropriate volume with sterile saline.
Radiochemical yields for 64Cu-DO3A-, 64Cu-CB-TE2A-, and
64Cu-NO2A-GSG-KCCYSL averaged 55%, 45%, and 57%,
respectively. Radiochemical purity of all 64Cu-labeled pep-
tides was found to be 98% pure.
Preparation of native Cu-peptides (natCu)
For nonradioactive Cu-labeling, 0.5 mg samples of DO3A-
(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and 64Cu-NO2A-
GSG-KCCYSL peptides were dissolved separately in 500mL
of ammonium acetate buffer (purged with nitrogen and
contained TCEP) with appropriate pH (as mentioned above)
containing 0.8 mM copper(II) sulfate-pentahydrate solution.
The solutions were heated at identical conditions used for
radiolabeling procedure and allowed to cool to room tem-
perature. natCu-peptides were then peak purified by RP-
HPLC. The native (natCu)-peptides were determined to be
98% pure by RP-HPLC analyses. Electrospray Ionization
mass-spectrometry was performed to check the integrity of
the peptides.
In vitro cell binding of radiolabeled KCCYSL peptides
Experiments were performed to test the ability of the
radiolabeled peptides to bind cell lines that express low to
moderate levels of EGFR-232 (MDA-MB-435) or normal
mammary epithelial cells (184A1) with negligible EGFR-2
expression. Cells grown in culture flasks were trypsinized,
released, and washed once in cell binding media (RPMI 1640
with 25 mM HEPES,8 pH 7.4, 0.2% BSA, 3 mM 1, 10-
phenanthroline). Cells (1105 cells/tube) were transferred to
microcentrifuge tubes containing 0.3 mL cell binding me-
dium and were incubated at 378C for different times (15
minutes, and 0.5, 0.75, 1, 1.5 and 2 hours) with 1105 counts
per minute (cpm) of radiolabeled peptides. After incubation,
the media were removed, and the cells were rinsed with ice-
cold 0.01 M PBS, pH 7.4, 0.2% BSA, and centrifuged. This
process was repeated twice. Radioactivity bound to the cells
was quantified in a Wallac g counter (PerkinElmer Life and
Analytical Sciences Inc.). Cell binding ability was reported as
total radioactivity in cpm that was bound to the cells.
Fifty-percent inhibitory concentration (IC50) binding
studies for radiopeptides were performed using cultured
MDA-MB-435 breast carcinoma cells. For competitive bind-
ing assays, MDA-MB-435 cells (2.5106 cells/tube) were in-
cubated with 2.5104 cpm 64Cu-DO3A or 64Cu-CB-TE2A or
64Cu-NO2A peptide and increasing concentrations of their
respective nonradioactive natCu-peptide counterparts (1012–
105 M) (n¼ 3 each). The cell-associated radioactivity was
measured in a Wallac g counter, and the binding affinity was
determined by the Grafit software program (Erithacus Soft-
ware Limited).
In vitro serum stability of the radiolabeled peptides was
tested by incubating 29.6 MBq of the respective peptide in
0.3 mL of mouse serum at 378C for 0.5, 1, 2, 4, and 24 hours,
respectively. At various time points, 40mL aliquots were re-
moved, and the proteins were precipitated with 40mL ace-
tonitrile. The samples were centrifuged at 12,500 rpm for 5
minutes, and the cleared lysate (*40 mL aliquots) was ana-
lyzed by RP-HPLC with a 0%–95% gradient acetonitrile in 30
minutes to assess the integrity of the radiolabeled peptides.
Pharmacokinetic studies of 64Cu-labeled peptides
in MDA-MB-435 xenograft SCID mice
SCID mice bearing MDA-MB-435 tumors (3 per time point)
were injected with approximately 0.185 MBq of different
radiolabeled peptides and were sacrificed by cervical dislo-
cation at 30 minutes and 1, 2, 4, and 24 hours postinjection
(p.i.), after which tissues and organs of interest were collected.
Gastrointestinal tract contents were not removed. The animal,
tissue, and organ samples were weighed, and counts were
determined with an automated g counter. Uptake of radio-
activity in the tumor and normal tissues and organs was ex-
pressed as a percentage of the injected radioactive dose per
gram (%ID/g). Whole blood %ID or %ID/g was determined
assuming the blood accounted for 6.5% of the body weight of
the mouse. For blocking experiments, the MDA-MB-435
breast tumor-bearing mice (n¼ 3) were preinjected with
100mg of natCu-DO3A or natCu-CB-TE2A or natCu-NO2A
peptides. After 10 minutes p.i., of the nonradiolabeled pep-
tide, 0.185 MBq of radiolabeled counterpart was injected and
the blocking efficiency was evaluated after 2 hours.
For reducing the kidney retention of the radiolabeled
peptides in mice, inhibition experiments with albumin frag-
ments were performed.33 Briefly, 335 mg of trypsin was ad-
ded to 3.0 g of BSA in 50 mM ammonium carbonate (15 mL).
The mixture was incubated at 378C for 24 hours. The trypsin-
digested sample was filtered using 50 kDa Centripep
(YM-50) centrifugal filters (Millipore). The filtrate containing
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albumin fragments <50 kDa was further fractionated using a
YM-3 filter (3 kDa cutoff), which yielded albumin fragments
<3 kDa (filtrate) and fragments with molecular weight range
of 3–50 kDa (residue). The effect of inhibition on renal uptake
of the radiolabeled peptides was tested in the presence of the
3–50 kDa albumin fraction.
In separate experiments, the 3–50 kDa albumin fragment
(200 mg) sample in normal saline (100 mL) was preinjected
into the MDA-MB-435 tumor-bearing mice (n¼ 3) via the tail
vein. After 5 minutes, 0.185 MBq of 64Cu-DO3A-(GSG)-
KCCYSL or 64Cu-CB-TE2A-(GSG)-KCCYSL or 64Cu-NO2A-
(GSG)-KCCYSL was administered into the mice. The mice
were sacrificed after 2 hours p.i., and the kidney uptake of
the radiolabeled peptides was measured in a g-counter.
Control experiments (n¼ 3) were run in parallel with pre-
injection of normal saline instead of albumin fragments.
MicroPET/CT imaging studies
In vivo microPET/CT of MDA-MB-435 tumor-bearing
mice with the radiolabeled peptides were performed as fol-
lows. MDA-MB-435 tumor-bearing mice were injected in the
tail vein with 12.0 MBq of 64Cu-DO3A- or 64Cu-CB-TE2A- or
64Cu-NO2A- (GSG)-KCCYSL and imaged at 2 hours p.i., in a
small animal PET scanner (MOSAIC small animal PET unit
[Philips]). This PET scanner has a transverse field of view of
12.8 cm and a gantry diameter of 21 cm. The scanner operates
in a three-dimensional (3D) mode. The mouse to be im-
aged was laser aligned at the center of the scanner field of
view for imaging. The microPET image reconstruction was
performed with a 3D row-action maximum-likelihood algo-
rithm. Small animal CT was performed for the purpose of
anatomic/molecular data fusion, and concurrent image re-
construction was performed with a Fanbeam (Feldkamp)
filtered-backprojection algorithm. Reconstructed Digital
Imaging and Communication in Medicine PET images were
imported into AMIRA 3.1 software (Visage Imaging, Inc.)
for subsequent image fusion with microCT and 3D vi-
sualization.
Statistical analysis
The data are presented as mean standard deviation. For
statistical analysis, a Student’s t-test was performed using
Prism software (Graphpad Software). A p-value 0.05 was
considered significant.
Results
Preparation and characterization of different
chelator-KCCYSL peptide
The peptides DO3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-
KCCYSL, and NO2A-(GSG)-KCCYSL were synthesized by
solid-phase synthesis with GSG spacers between the chelators
and the amino termini of the peptides to avoid possible steric
hindrances. The chemical structures of different chelator-
peptides are shown in Figure 1. Nonradioactive Cu-chelator-
peptides were prepared by heating aqueous solutions of the
peptides with CuSO4.5H2O at temperatures similar to those
described for radioactive peptides. Nonradiolabeled copper-
labeled peptides were purified and analyzed by mass spec-
trometry before cell binding assays. The calculated and
observed molecular weight of natCu-peptide was 1365.0,
1364.7.0 (DO3A-peptide), 1302.0, 1301.8 (CB-TE2A–peptide),
and 1326.0, 1325.8 (NO2A-peptide), respectively.
For radiolabeling, DO3A-(GSG)-KCCYSL was dissolved in
0.1 M ammonium acetate buffer (pH 5.5), CB-TE2A-(GSG)-
KCCYSL in 0.4 ammonium acetate (pH 7.0) buffer, and NO2A-
(GSG)-KCCYSL in ammonium acetate (0.4 M) pH 6.8. 64CuCl2
was added to the solutions and heated at different tempera-
tures (858C, 90 minutes) for DO3A and CB-TE2A peptides and
(758C for 60 minutes) for NO2A-peptide, respectively. The
radiolabeled peptides were purified by RP-HPLC in order to
separate them from their respective nonradiolabeled counter-
parts. The retention times of 64Cu-DO3A-, 64Cu-CB-TE2A-, and
64Cu-NO2A-GSG-KCCYSL were 12.8, 13.3, and 13.0 minutes,
respectively, under identical RP-HPLC conditions. All the
peptides were obtained at high radiochemical purity with a
reasonable radiochemical yield (Table 1).
Studies to test the ability of the 64Cu-radiolabeled peptides
to bind MDA-MB-435 breast carcinoma cells known to ex-
press EGFR-232 or normal mammary epithelial cells (184A1)
with negligible expression of EGFR-2 were performed. The
64Cu-DO3A, 64Cu-CB-TE2A, and 64Cu-NO2A peptides were
able to bind EGFR-2 expressing MDA-MB-435 cells in a time-
dependent manner. The peptides exhibited a similar cell
binding profile up to 45 minutes, beyond which binding of
the peptides to MDA-MB-435 cells appeared to be saturated.
Further increase in cell binding was not observed up to 2
hours (Fig. 2). The peptides demonstrated less or no binding
to 184A1 cells, indicating the specificity of the radiolabeled
peptides for EGFR-2 expressing cells.
Receptor binding affinity studies with radiolabeled pep-
tides in the presence of their respective nonradioactive coun-
terparts were carried out using cultured human MDA-MB-435
breast carcinoma cells. The radiolabeled peptides demon-
strated nanomolar affinity with IC50 values of 42 10.2 nM
(64Cu-DO3A-peptide), 31 7.9 nM (64Cu-CB-TE2A-peptide),
and 44 6.6 nM (64Cu-NO2A-peptide) (mean standard de-
viation, n¼ 3, Table 1), respectively. The IC50 values suggest
that the radiolabeled peptides with different chelators pos-
sessed comparable EGFR-2 binding affinities.
To determine their metabolic stability, the radiolabeled
peptides were incubated in mouse serum for various time
points in vitro, at 378C. As determined by RP-HPLC, the
radiolabeled peptides were stable in serum for periods up to
2 hours. However, an additional peak was observed with all
three radiolabeled peptides, which eluted very close to the
original radiolabeled peak, indicating degradation of peptide
with passage of time at 4 and 24 hours (data not shown).
Biodistribution and imaging studies
Detailed in vivo pharmacokinetic studies with all the radi-
olabeled peptides in SCID mice bearing MDA-MB-435 xeno-
grafts were performed and are summarized in Tables 2–4. At
2 hours p.i., 89.4 3.6%ID had been excreted from the mice
using 64Cu-DO3A-peptide conjugate in comparison with
95.2 0.48%ID of 64Cu-CB-TE2A-peptide and 96.05 0.15%ID
of 64Cu-NO2A-peptide conjugate, respectively. Overall clear-
ance of all the 64Cu-chelated peptides proceeded primarily
through the renal system, with *2.4 0.36%ID (64Cu-DO3A-
peptide), 0.54 0.05%ID (64Cu-CB-TE2A-peptide), and 0.48
0.07%ID (64Cu-NO2A-peptide) being excreted through the
hepatobiliary system.
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The disappearance of different radiolabeled peptides from
the blood was comparable at initial time points (0.5, 1, and 2
hours) tested. For instance, at the end of 2 hours p.i., peptide
retention in the blood was 0.20 0.08%ID/g, 0.05 0.01%ID/g,
and 0.08 0.01%ID/g for 64Cu-DO3A-, 64Cu-CB-TE2A-, and
64Cu-NO2A-peptides, respectively. Despite lower blood values
observed for CB-TE2A and NO2A peptides compared with
DO3A-peptide at or beyond 2 hours time point, the values were
not statistically different (p> 0.05).
Unstable copper compounds are known to exhibit higher
retention in the liver in vivo. In this study, the retention of
64Cu in the liver with 64Cu-DO3A-peptide was observed to
be higher than 64Cu-CB-TE2A- or 64Cu-NO2A-peptide at all
time points, suggesting the relative stable chelation of 64Cu
with CB-TE2A and NO2A. The difference in radiolabled
uptake in the liver between 64Cu-DO3A- and 64Cu-CB-TE2A-
peptide (n¼ 3, p¼ 0.001), 64Cu-DO3A-, and 64Cu-NO2A-
peptide (n¼ 3, p¼ 0.03) was statistically different, whereas
the uptake between 64Cu-NO2A- and 64Cu-CB-TE2A-peptide
was comparable and not statistically significant (n¼ 3, p> 0.05).
The tumor uptake of the 64Cu-labeled peptides was compa-
rable at 0.5 hours p.i. (0.91 0.12%ID/g, 64Cu-DO3A-peptide),
FIG. 1. Chemical structures of DO3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and NO2A-(GSG)-KCCYSL.
Table 1. Characterization of 64Cu Labeled Peptides
Peptide RP-HPLC (tr-min) Labeling yield (%) Radiochemical purity Receptor affinity (IC50, nM)
64Cu-DO3A-GSG-KCCYSL 12.8 55 98 42 10.2
64Cu-CB-TE2A-GSG-KCCYSL 13.3 45 98 31 7.9
64Cu-NO2A-GSG-KCCYSL 13.0 57 98 44 6.6
The IC50 was determined using corresponding nonradiolabeled counterparts. Details are given in Materials and Methods section.
IC50, 50% inhibitory concentration; RP-HPLC, Reverse phase-high performance liquid chromatography.
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(0.98 0.31%ID/g, 64Cu-CB-TE2A-peptide), and
(0.78 0.03%ID/g, 64Cu-NO2A-peptide). Also, in the later time
points, there were no significant differences in the tumor uptake
between the three radiolabeled peptides. For instance, at the 2
hours time point, the tumor uptake of 64Cu-DO3A-peptide was
0.54 0.06%ID/g compared with that of 0.32 0.08%ID/g for
64Cu-CB-TE2A- and 0.61 0.06%ID/g for 64Cu-NO2A-peptide,
respectively.
The tumor-to-blood ratio was found to be significantly
different between 64Cu-DO3A/64Cu-CB-TE2A peptides
(n¼ 3, p¼ 0.04) and 64Cu-DO3A/64Cu-NO2A peptides
(n¼ 3, p¼ 0.045), whereas there was no significant differ-
ence between 64Cu-CB-TE2A/64Cu-NOTA peptides for all
time points ( p> 0.05). Similarly, tumor-to-liver ratios were
also significantly different between 64Cu-DO3A/64Cu-CB-
TE2A (n¼ 3, p¼ 0.027) and 64Cu-DO3A/64Cu-NO2A (n¼ 3,
p¼ 0.01) peptides, respectively. These results suggest that
64Cu-DO3A peptide uptake in the liver was high compared
with 64Cu-CB-TE2A and 64Cu-NO2A peptides. However, no
major difference was observed between 64Cu-CB-TE2A
and 64Cu-NO2A peptides, suggesting their uptake was
comparable in liver tissue at all time points. No variation in
tumor-to-muscle ratio was observed between the three
radiolabeled peptides (Tables 2–4), and the differences in
values were not statistically significant (n¼ 3, p> 0.05). In-
creased tumor-to-liver tissue ratio of both 64Cu-CB-TE2A
and 64Cu-NO2A peptides compared with 64Cu-DO3A pep-
tide suggests less transchelation of 64Cu from the former two
chelator-peptides.
The retention of radiolabeled peptides was observed to be
high in kidneys. Radioactivity in the kidneys decreased from
6.37 1.44%ID/g at 0.5 hours to 4.27 0.84%ID/g at 2 hours
and 1.49 0.24%ID/g at 24 hours, for 64Cu-DO3A-peptide.
Similarly, the radioactivity declined from 7.11 0.75%ID/g
after 0.5 hours p.i., to 6.43 1.56%ID/g at 2 hours, and
3.2 0.23%ID/g at 24 hours for 64Cu-CB-TE2A-peptide.
64Cu-NO2A-peptide uptake in kidneys was 7.87 0.96 at 0.5
hours, which declined to 4.23 1.00 at 2 hours, and
0.68 0.07 at 24 hours. Further statistical comparison of
FIG. 2. Epidermal growth factor receptor-2 receptor
binding properties of the radiolabeled 64Cu-DO3A-
(GSG)-KCCYSL, 64Cu-CB-TE2A-(GSG)-KCCYSL, and 4Cu-
NO2A-(GSG)-KCCYSL peptides. Approximately, 1.0105
MDA-MB-435 breast carcinoma or normal mammary epi-
thelial cells/tube were incubated at 378C for different time
intervals with 100,000 counts per minute radioligand. The
radiolabled peptides bound to human MDA-MB-435 breast
carcinoma cells. 64Cu-DO3A- peptide (); 64Cu-CB-TE2A-
peptide (&) and 64Cu-NO2A- peptide (&).Very minimal
or no binding was observed with normal mammary epi-
thelial (184A1) cells using 64Cu-DO3A-peptide (~) or 64Cu-CB-
TE2A-peptide (^) or 64Cu-NO2A- peptide (*), respectively.
Table 2. Pharmacokinetic Studies of 64Cu-DO3A-GSG-KCCYSL Using MDA-MB-435 Tumor-Bearing SCID Mice
Tissues 0.5 hour 1 hour 2 hours 2 hours block 4 hours 24 hours
Percent injected dose/g (%ID/g)a
Tumor 0.91 0.12 0.73 0.15 0.54 0.06 0.29 0.09b 0.45 0.20 0.27 0.02
Blood 1.08 0.22 0.35 0.14 0.20 0.08 0.18 0.04 0.16 0.12 0.15 0.02
Brain 0.05 0.01 0.03 0.01 0.03 0.01 0.02 0.01 0.02 0.01 0.03 0.01
Heart 0.57 0.03 0.34 0.17 0.35 0.09 0.24 0.02 0.36 0.21 0.30 0.05
Lung 1.40 0.07 0.96 0.15 0.79 0.07 0.70 0.09 0.64 0.20 0.56 0.12
Liver 2.30 0.21 1.72 0.94 1.68 0.42 1.47 0.53 1.65 1.01 1.07 0.11
Spleen 0.51 0.07 0.40 0.14 0.57 0.31 0.52 0.40 0.68 0.44 0.54 0.03
Stomach 0.54 0.20 0.56 0.26 0.36 0.11 0.29 0.10 1.14 1.00 0.14 0.08
Kidneys 6.37 1.44 4.32 0.57 4.27 0.84 4.12 1.23 2.96 0.31 1.49 0.24
Muscle 0.23 0.02 0.08 0.03 0.06 0.01 0.05 0.01 0.07 0.04 0.05 0.01
Pancreas 0.31 0.10 0.14 0.09 0.23 0.05 0.18 0.07 0.18 0.09 0.17 0.08
Bone 0.26 0.09 0.12 0.05 0.15 0.08 0.12 0.05 0.12 0.06 0.03 0.01
Percent injected dose (%ID)
Intestines 2.05 0.17 2.34 1.3 3.1 1.50 3.4 0.40 3.3 1.94 1.11 0.14
Urine 81.11 1.20 88.4 4.5 89.4 3.60 87.8 0.57 90.0 5.40 94.9 0.50
Uptake ratio of tumor/normal tissue
Tumor/blood 0.84 2.08 2.70 — 2.40 1.80
Tumor/muscle 3.95 9.12 9.00 6.40 5.40
Tumor/liver 0.39 0.42 0.32 0.27 0.20
aData are presented as %ID/g SD except for intestines and urine, values for which are expressed as%ID standard deviation (n¼ 3).
bp¼ 0.03, significance comparison between the tumor uptake of radiolabeled peptide in the absence and presence of its nonradiolabeled
counterpart at 2 hours p.i.
p.i., postinjection; SD, standard deviation.
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kidney uptake values for earlier time points (0.5, 1, and 2
hours) was comparable and not statistically significant
between 64Cu-CB-TE2A-/64Cu-DO3A-peptide, 64Cu-DO3A-/
64Cu-NO2A-peptide, or 64Cu-NO2A-/64Cu-CB-TE2A-peptide
(n¼ 3, p> 0.05). With regard to the radioactivity retention in
lungs, 64Cu-DO3A-peptide was relatively higher at all time
points compared with 64Cu-CB-TE2A and 64Cu-NO2A pep-
tides, respectively (Tables 2–4). Significant difference was
noted in the values between 64Cu-DO3A-/64Cu-CB-TE2A-
peptide (n¼ 3, p¼ 0.001) and 64Cu-DO3A-/64Cu-NO2A-pep-
tide (n¼ 3, p¼ 0.02), suggesting more lung retention of
64Cu-DO3A-peptide at all time points. The lung uptake values
Table 3. Pharmacokinetic Studies of 64Cu-CB-TE2A-GSG-KCCYSL Using MDA-MB-435 Tumor-Bearing SCID Mice
Tissues 0.5 hour 1 hour 2 hours 2 hours block 4 hours 24 hours
Percent injected dose/g (%ID/g)a
Tumor 0.98 0.31 0.64 0.08 0.32 0.17 0.16 0.07b 0.17 0.05 0.10 0.03
Blood 1.18 0.20 0.28 0.12 0.05 0.01 0.02 0.01 0.02 0.01 0.011 0.01
Brain 0.04 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.007 0.001
Heart 0.42 0.31 0.15 0.03 0.06 0.02 0.05 0.03 0.07 0.01 0.012 0.001
Lung 1.13 0.16 0.46 0.09 0.24 0.02 0.20 0.05 0.18 0.02 0.05 0.002
Liver 0.68 0.11 0.52 0.02 0.45 0.05 0.37 0.10 0.40 0.03 0.29 0.05
Spleen 0.36 0.11 0.20 0.08 0.12 0.06 0.10 0.05 0.10 0.01 0.01 0.003
Stomach 0.25 0.08 0.18 0.10 0.13 0.06 0.15 0.02 0.21 0.12 0.03 0.001
Kidneys 7.11 0.75 6.72 0.91 6.43 1.56 6.94 1.47 5.96 0.89 3.18 0.23
Muscle 0.21 0.07 0.06 0.01 0.03 0.01 0.05 0.01 0.02 0.01 0.007 0.001
Pancreas 0.32 0.11 0.14 0.04 0.05 0.01 0.02 0.00 0.05 0.01 0.04 0.001
Bone 0.20 0.05 0.07 0.02 0.04 0.01 0.03 0.01 0.04 0.01 0.03 0.001
Percent injected dose (%ID)
Intestines 1.02 0.19 2.0 2.10 0.75 0.07 0.73 1.27 1.3 1.90 1.0 0.14
Urine 78.2 9.20 91.2 3.74 95.2 0.48 93.7 4.30 95.3 1.40 98.0 2.40
Uptake ratio of tumor/normal tissue
Tumor/blood 0.83 2.20 6.40 — 8.50 10.00
Tumor/muscle 4.00 10.70 10.71 17.00 14.20
Tumor/liver 1.40 1.20 0.70 0.42 0.34
aData are presented as %ID/g standard deviation except for intestines and urine, values for which are expressed as%ID SD (n¼ 3).
bp¼ 0.024, significance comparison between the tumor uptake of radiolabeled peptide in the absence and presence of its nonradiolabeled
counterpart at 2 hours p.i.
Table 4. Pharmacokinetic Studies of 64Cu-NO2A-GSG-KCCYSL Using MDA-MB-435 Tumor-Bearing SCID Mice
Tissues 0.5 hour 1 hour 2 hours 2 hours block 4 hours 24 hours
Percent injected dose/g (%ID/g)a
Tumor 0.78 0.03 0.64 0.04 0.61 0.06 0.32 0.09b 0.43 0.02 0.1 0.01
Blood 1.29 0.09 0.33 0.11 0.08 0.01 0.10 0.04 0.05 0.02 0.01 0.01
Brain 0.05 0.01 0.02 0.01 0.02 0.01 0.01 0.001 0.00 0.00 0.00 0.00
Heart 0.40 0.05 0.16 0.06 0.04 0.01 0.08 0.02 0.04 0.02 0.07 0.02
Lung 1.21 0.08 0.49 0.07 0.22 0.08 0.34 0.07 0.15 0.06 0.10 0.03
Liver 0.90 0.09 0.55 0.07 0.48 0.05 0.57 0.20 0.34 0.10 0.27 0.05
Spleen 0.41 0.07 0.19 0.11 0.11 0.05 0.11 0.05 0.08 0.05 0.07 0.02
Stomach 0.37 0.04 0.18 0.03 0.14 0.04 0.20 0.10 0.13 0.03 0.10 0.05
Kidneys 7.87 0.96 6.51 0.63 4.23 1.00 6.70 0.89 1.37 0.28 0.68 0.07
Muscle 0.20 0.05 0.06 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Pancreas 0.34 0.09 0.10 0.08 0.09 0.03 0.05 0.01 0.03 0.01 0.03 0.01
Bone 0.08 0.05 0.04 0.05 0.04 0.01 0.02 0.01 0.02 0.01 0.01 0.01
Percent injected dose (%ID)
Intestines 1.2 0.13 1.1 0.27 1.06 0.14 1.30 0.60 1.33 0.35 0.5 0.10
Urine 84.4 1.93 90.1 4.04 96.0 0.15 93.9 1.06 96.7 0.13 98.1 0.14
Uptake ratio of tumor/normal tissue
Tumor/blood 0.60 1.94 7.62 — 8.60 3.00
Tumor/muscle 4.00 10.70 10.71 17.00 14.20
Tumor/liver 0.86 1.16 1.27 1.26 0.11
aData are presented as %ID/g standard deviation except for intestines and urine, values for which are expressed as %ID standard
deviation (n¼ 3).
bp¼ 0.027, significance comparison between the tumor uptake of radiolabeled peptide in the absence and presence of its nonradiolabeled
counterpart at 2 hours p.i.
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between 64Cu-NO2A- and 64Cu-CB-TE2A-peptides were
comparable and did not significantly differ ( p> 0.05).
Blocking studies were performed with 100mg of respective
natCu-peptides 15 minutes before the injection of the radi-
olabeled peptides in tumor mice (n¼ 3). As a positive control,
another set of mice (n¼ 3) was injected with respective radi-
olabeled peptides only. The results demonstrated that tumor
uptake of radiolabeled peptide was blocked by 46% (DO3A-
peptide, p¼ 0.03), 50% (CB-TE2A-peptide, p¼ 0.024), and 48%
(NO2A-peptide, p¼ 0.027), respectively (Tables 2–4).
It is well known that high and persistent renal retention of
radiolabeled peptides is a concern when designing receptor-
targeted radiopharmaceuticals. In an attempt to study an
agent that could interfere with kidney retention of the radi-
olabeled peptides, albumin fragments33 were used as inhibit-
ing agents. The renal uptake of the radiolabeled peptides with
and without albumin fragments (3–50 kDa) is shown in
(Fig. 3). The kidney retention of the radiolabeled peptides
with 64Cu-DO3A-, 64Cu-CB-TE2A-, and 64Cu-NO2A-(GSG)-
KCCYSL was blocked in the presence of albumin fragments
by 29%, 47%, and 47.5% (n¼ 3 each, p 0.05), respectively.
Observations from small animal microPET experiments
performed in SCID mice bearing MDA-MB-435 tumors at
different times after intravenous injection of 12.0 MBq of
each 64Cu-DO3A-, 64Cu-CB-TE2A, and 64Cu-NO2A-(GSG)-
KCCYSL are depicted in Figure 4. All the images were ac-
quired at 2 hours p.i., of the radiolabeled peptides. Tumors
could be easily visualized with radiolabeled peptides. For
64Cu-DO3A-peptide, the abdominal uptake and retention
appeared high compared with 64Cu-CB-TE2A- and 64Cu-
NO2A-peptides, which showed relatively less retention in
the gastrointestinal tract and liver. A more notable difference
in retention was observed in liver tissue for the 64Cu-DO3A-
peptide,which was higher compared with 64Cu-CB-TE2A- or
64Cu-NO2A-KCCYSL, which agrees with the biodistribution
data. Substantial uptake of all radiolabeled peptides in the
kidneys was evident, indicating that theses tracers are
mainly excreted through the renal route.
Discussion
Our study demonstrates that a phage derived peptide,
KCCYSL, that binds the extracellular domain of EGFR-2,11,18
once synthesized with a bi-functional chelator and radi-
olabeled with 64Cu, can be developed into a PET imaging
agent for detection of breast tumors in vivo. Though other
groups have reported peptides derived from phage display
that bind EGFR-2,13,34,35 our studies are the first to demon-
strate in vivo in a animal model that an EGFR-2 targeting
peptide selected by phage display can be exploited as an
SPECT or PET radioimaging agent.18
DOT3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and
NO2A-(GSG)-KCCYSL were synthesized and efficiently
radiolabeled with 64Cu. One potential problem with cyste-
ine-containing peptide(s) in aqueous buffers especially at
neutral or alkaline pH is the oxidation of its thiol group to
form disulfide bonds during radiolabeling reactions. Though
the oxidation may be minimal in acidic pH (as in DO3A
labeling), the chances are relatively high in near neutral pH
such as the reaction conditions used in CB-TE2A and NO2A.
To overcome this situation, the reaction buffers were exten-
sively purged with nitrogen to keep oxygen levels minimal
and also contained reducing agent TCEP to prevent the
formation of disulfide bonds.
All the radiolabeled peptides bound to EGFR-2 expressing
MDA-MB-435 breast carcinoma cells, whereas minimal
binding was observed with normal mammary cells (184A1).
MDA-MB-435 human breast carcinoma cells were originally
isolated from a pleural effusion of a woman with metastatic
breast adenocarcinoma.36 Rae at al. speculated in 2004 that
the original MDA-MB-435 cancer cells were lost early after
their establishment and found to be identical to the M-14
melanoma cell line.37 However, a recent report based on the
different origin of these cell lines indicated that both MDA-
MB-435 and M-14 cell lines are consistent with MDA-MB-435
breast cancer origin38 and that some poorly differentiated
breast tumors can exhibit lineage infidelity and express
markers associated with both epithelial and melanomas.
Given this, the MDA-MB-435 breast carcinoma cell line has
been widely used as a breast carcinoma model and remains
one of the most reliable in vivo models of human breast
cancer.
In vitro competition studies with unlabeled peptides
demonstrated specificity of the radiolabeled peptide for
breast carcinoma cells. Comparable binding affinities were
noted with the three radiolabeled peptides. One would an-
ticipate that binding affinity differences between the pep-
tides may arise due to the use of different chelators. Previous
studies with somatostatin receptor targeting DOTA-[Tyr3]-
octreotide peptide analogs suggested that relatively small
changes in a radiolabeled peptide, such as altering the
chelator, can markedly change the receptor binding profile.39
FIG. 3. Renal blocking studies with bovine serum albumin
fragments. Albumin fragments (200mg) were preinjected in
the mice 5 minutes before the injection of radiolabeled pep-
tides (0.185 MBq). The kidney uptake of the radioligands in
mice with and without albumin fragments was measured in a
g-counter. Inhibition in the uptake of 64Cu-DO3A-(GSG)-
KCCYSL (29%, *p¼ 0.037), 64Cu-CB-TE2A-(GSG)-KCCYSL
(47%, **p¼ 0.02), and 64Cu-NO2A-(GSG)-KCCYSL (48%,
***p¼ 0.032) in the presence of albumin fragments are shown.
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On the contrary, we did not observe any marked changes in
the binding affinity profile of all three radiolabeled peptides
tested to bind the breast carcinoma cells.
Comparative in vivo studies of 64Cu-DO3A-, 64Cu-CB-
TE2A-, and 64Cu-NO2A- (GSG)-KCCYSL indicated reason-
able tumor uptake of these peptides. 64Cu-CB-TE2A-(GSG)-
KCCYSL conjugate demonstrated significant disappearance
from the tumor, at 24 hours p.i., compared with 64Cu-DO3A-
(GSG)-KCCYSL, which had slower disappearance for the
same time period (Tables 2 and 3). The delayed tumor tissue
disappearance pattern of the 64Cu-DO3A-radioconjugate
could be due to a trapping mechanism, such as transchela-
tion of the radiometal from the chelator to intracellular
protein(s).22,26,40 Moreover, significant transchelation of the
64Cu-DO3A-peptide to serum proteins occurs in blood,23,41
and the protein-bound 64Cu form may be transported back
into the blood, which over time decreases target tissue:blood
ratios.
All the radiolabeled peptides demonstrated significant
blood disappearance rates, whereas the liver clearance was
modest with relatively more retention of 64Cu-DO3A- com-
pared with 64Cu-CB-TE2A and 64Cu-NO2A peptides. Un-
stable copper compounds in vivo (e.g., DO3A-peptides) are
known to exhibit high retention in the liver that could be
likely due to transchelation.42 The use of the 64Cu-DO3A
chelation system can result in release of uncoordinated 64Cu
by decomposition in the blood or transchelation in the liver,
resulting in elevated uptake in liver tissue.23,41 On the other
hand, CB-TE2A and NO2A chelator-peptides demonstrated
less tranchelation of the bound metal. Boswell et al. observed
that the 64Cu-labeled chelator CB-TE2A during biodistribu-
tion studies in normal rats underwent significantly less
transchelation in liver.25 In this study, it was shown that
transchelation of 64Cu from 64Cu-DOTA was 39% 1% at 1
hour, whereas transchelation of 64Cu from 64Cu-CB-TE2A
was 12% 7% for the same time period.25 Also, previous
studies indicated that the injection of [64Cu]Cu2þ alone in
mice resulted in half the injected dose (*54%) concentrated
in the liver after 2 hours.43 Also, oral administration of
copper acetate in tumor-bearing mice revealed the accumu-
lation of copper in liver (*62.1 mg/g tissue) and kidneys
(*4.8 mg/g tissue).43 Studies with 64Cu-NO2A-RGD-bom-
besin peptide uptake resulted in less uptake in the liver,
compared to 64Cu tracers42 suggesting the high kinetic
stability of the radiotracer. Another study with 64Cu-NO2A-
bombesin analogs also reported the stability of NO2A pep-
tides in vivo.28
Nonspecific accumulation of radioactivity in the kidneys
is often associated with the use of radiolabeled peptides
in vivo.44 The kidney retention of copper KCCYSL peptides
was found to be substantially high. Similar kidney retention
of peptides with 64Cu-labeled azamacrocycles, including that
of 64Cu-CB-TE2A-Y3-TATE and 64Cu-CB-TE2A-somatostatin
receptor subtype 2 selective antagonist (sst2-ANT), was
previously reported.25,45 Recent studies indicated that ad-
ministering albumin fragments could reduce the renal up-
take of radiolabeled peptides.33 Since only a small fraction
of total albumin passes through the glomerular membrane,
it was hypothesized that the use of albumin fragments
could competitively inhibit the uptake of radiolabeled
peptides in the kidneys.33 In the present study, biodis-
tribution studies with an attempt to block the in vivo kidney
uptake of 64Cu-DO3A-, 64Cu-CB-TE2A-, and 64Cu-NO2A-
(GSG)-KCCYSL in the presence of albumin fragments
resulted in a partial inhibition in the uptake of radiotracers
by the kidneys.
FIG. 4. MicroPET/CT of MDA-MB-435 tumor-bearing mice. 64Cu-DO3A-(GSG)-KCCYSL, 64Cu-CB-TE2A-(GSG)-
KCCYSL, or 64Cu-NO2A-(GSG)-KCCYSL 12.0 (MBq) each, was injected into the tail vein of SCID mice bearing MDA-MB-435
tumor xenograft. Imaging was acquired 2 hours postinjection, of the radiolabeled peptides in a PET scanner. The PET images
were fused with conventional microCT images to validate regions of increased radiolabeled peptide uptake. The figures
depict PET/CT images with (A) 64Cu-DO3A-(GSG)-KCCYSL; (B) 64Cu-CB-TE2A-(GSG)-KCCYSL; and (C) 64Cu-NO2A-
(GSG)-KCCYSL (t, tumor; l, liver; k, kidney; i, intestine). CT, computed tomography; PET, positron emission tomography.
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Similar to radiolabeled GSG-KCCYSL peptides, corre-
sponding nonradiolabeled peptides presumably undergo
faster blood clearance, and demetallation from these pep-
tides may also occur in the liver. This presumably could have
been attributed to partial blocking of tumoral uptake of
the radiolabeled peptides in the presence of their non-
radiolabeled counterparts during biodistribution studies.
Thus, lack of longer residence time of the competing mole-
cule and its uptake in nontarget tissues including kidney
could result in less efficient blocking of the radioligand up-
take in tumor unlike large molecules such as antibodies,
which have much longer circulation times in vivo.46
Small-animal PET/CT studies with all three radiolabeled
peptides demonstrated reasonable tumor uptake and reten-
tion. In spite of similar tumor uptake by these peptides,
differences in uptake and retention of these compounds in
nontarget tissues were found. For the 64Cu-DO3A-peptide,
the image revealed significant activity in the liver, gastroin-
testinal tract, and the kidneys. The image obtained with
64Cu-CB-TE2A and 64Cu-NO2A-peptides, however, demon-
strated relatively reduced activity in the liver and the gastro-
intestinal tract with comparable retention in the kidneys.
Likewise, biodistribution and imaging studies with 64Cu-CB-
TE2A-Y3-TATE, a somatostatin receptor targeting peptide,
showed low uptake in liver and blood and more in the kid-
neys.31 Recent studies with 64Cu-CB-TE2A-ReCCMSH(Arg11),
a melanocortin receptor targeting peptide, demonstrated re-
duced uptake in liver and blood and a modest uptake in the
kidneys compared with 64Cu-DOTA-ReCCMSH(Arg11).47 Ta-
ken together,64Cu-CB-TE2A- and 64Cu-NO2A-peptides dem-
onstrated better tumor-to-background ratios and nontarget
tissue clearance compared with the DO3A-peptide. Overall, the
cross-bridged cyclam chelator CB-TE2A and NOTA exhibit
comparable stability, thus enabling efficient 64Cu-radiophar-
maceutical applications with biological targeting molecules
such as the KCCYSL peptide.
Conclusions
The peptides 64Cu-DO3A-(GSG)-KCCYSL, 64Cu-CB-TE2A-
(GSG)-KCCYSL, and 64Cu-NO2A-(GSG)-KCCYSL were eval-
uated as agents for PET imaging of breast carcinoma. The 64Cu-
stabilization properties of CB-TE2A and NOTA compared with
those of DOTA resulted in improved blood disappearance
and lower retention in liver and the gastrointestinal tract, with
improved tumor-to-nontarget tissue ratios for 64Cu-CB-TE2A-
and 64Cu-NO2A-GSG-KCCYSL. Thus, CB-TE2A and NO2A-
peptides appear to be better candidates for application as di-
agnostic PET agents for EGFR-2 expressing breast cancers.
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